Cytel Inc. Hires Biopharmaceutical Development Veteran Jim Baker to Support Expansion of its Clinical Research Offerings
Published: Mar 21, 2011
CAMBRIDGE, Mass., March 18, 2011/PRNewswire/ -- Cytel Inc., premier provider of clinical trial design and implementation services and software, proudly announced today the addition of pharmaceutical and biotech industry veteran Jim Baker as Vice President, Clinical Research Services.
Over his 28 year career, Baker has demonstrated biopharmaceutical development leadership at some of the world's top pharmaceutical, biotech and clinical research firms including Amgen®, Wyeth® and Parexel®. Most recently Baker served as Senior Director of Study Standards Implementation at Millennium®.
Jim Baker is respected not only for his cross-functional experience spanning both development planning and clinical operations, but also equally for his in-depth trial data management knowledge.
Cytel CEO Ranganath Nayak remarked: "Jim's talent and track record are a precise match for Cytel's expanding line of innovative Clinical Research Services. Our customers will be happy that we have someone who has walked many a mile in their shoes and understands not only what their needs are but also how best to align Cytel's capabilities with those needs."
Baker has officially assumed his new position and it is our distinct pleasure to welcome him as the newest member of the Cytel management team.
Cytel pioneered the statistical science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider. Cytel software is used by 47 of the top 50 biopharmaceutical companies to design, monitor and analyze their clinical trials.
SOURCE Cytel Inc.